FDA-Approved Treatment for Treatment-Resistant Depression
Spravato (esketamine) Therapy represents an innovative breakthrough in treating treatment-resistant depression. Our carefully structured program combines FDA-approved Spravato nasal spray with comprehensive monitoring in a controlled, comfortable setting.
Each treatment session begins with a thorough pre-treatment assessment, followed by medication administration under the direct supervision of our qualified healthcare providers. Patients remain in our specially designed treatment rooms for two hours post-administration, ensuring both safety and comfort throughout the experience.
Our Spravato treatment protocol typically starts with twice-weekly sessions for the first month, followed by personalized maintenance schedules based on your response and needs. Our team closely monitors your progress and integrates this therapy with your overall mental health care plan.
Quick Facts
Spravato is FDA-approved for treatment-resistant depression and MDD with suicidal ideation.
Esketamine nasal spray self-administered under clinical supervision.
Each session requires a 2-hour monitored observation period post-dose.
Twice-weekly sessions for the first month, then personalised maintenance.
Spravato may be covered by insurance — our team can assist with prior authorisation.
Who This Service Can Help
Treatment-Resistant Depression
For patients who have not responded to at least two antidepressant treatments, Spravato offers an FDA-approved path forward.
MDD with Suicidal Ideation
Spravato is specifically FDA-approved for major depressive disorder with acute suicidal ideation or behaviour.
Persistent Low Mood
Patients experiencing chronic, low-grade depression that hasn’t fully responded to standard therapies may benefit significantly.
Anxiety with Depression
Co-occurring anxiety and depression that has been difficult to treat with oral medications alone.
Post-Partum Depression
Spravato may be considered for postpartum depression in cases where rapid symptom relief is clinically indicated.
Bipolar Depression
As part of a carefully supervised treatment plan, Spravato may provide relief for depressive phases of bipolar disorder.
Frequently Asked Questions
Have more questions? Our team is here to help you make an informed decision about your care.
How is Spravato different from ketamine infusions?
Spravato (esketamine) is FDA-approved and administered as a nasal spray rather than intravenously. It may be covered by insurance and is specifically indicated for treatment-resistant depression, whereas IV ketamine is used off-label.
Why is a 2-hour observation required?
Due to the risk of dissociation and sedation, FDA guidelines require patients to be monitored for at least 2 hours after each dose. You cannot drive on the day of treatment — a designated driver or rideshare is required.
How quickly will I feel results?
Many patients report improvement within the first 1–4 weeks. Spravato is known for its relatively rapid onset compared to oral antidepressants, which typically take 4–6 weeks.
Can I continue my other antidepressants?
Yes. Spravato is used in combination with an oral antidepressant. Our clinical team will review your current medications to ensure compatibility and optimal outcomes.
Is Spravato safe for long-term use?
Spravato has been studied for long-term maintenance use. Our team monitors your response at every session and adjusts frequency as clinically appropriate to balance efficacy with safety.